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Abstract: Cancer is one of the main global health problems. In order to develop novel antitumor agents, we synthesized
3,4-dihydropyrimidine-2(1H)-one (DHPM) and 2,6-diaryl-substituted pyridine derivatives as potential antitumor struc-
tures and evaluated their cytotoxic effects against several cancer cell lines. An easy and convenient method is reported
for the synthesis of these derivatives, employing cobalt ferrite (CoFe2O4@SiO2 -SO3H) magnetic nanoparticles under
microwave irradiation and solvent-free conditions. The structural characteristics of the prepared nanocatalyst were inves-
tigated by FTIR, XRD, SEM, and TGA techniques. In vitro cytotoxic effects of the synthesized products were assessed
against the human breast adenocarcinoma cell line (MCF-7), gastric adenocarcinoma (AGS), and human embryonic
kidney (HEK293) cells via MTT assay. The results indicated that compound 4r (DHPM derivative) was the most toxic
molecule against the MCF-7 cell line (IC50 of 0.17 µg/mL). Moreover, compounds 4j and 4r (DHPM derivatives) showed
excellent cytotoxic activities against the AGS cell line, with an IC50 of 4.90 and 4.97 µg/mL, respectively. Although
they are pyridine derivatives, compounds 5g and 5m were more active against the MCF-7 cell line. Results showed
that the candidate compounds exhibited low cytotoxicity against HEK293 cells. The kinesin Eg5 inhibitory potential of
the candidate compounds was evaluated by molecular docking. The docking results showed that, among the pyridine
derivatives, compound 5m had the most free energy of binding (–9.52 kcal/mol) and lowest Ki (0.105 µM), and among
the pyrimidine derivatives, compound 4r had the most free energy of binding (–7.67 kcal/mol) and lowest Ki (2.39 µM).
Ligand-enzyme affinity maps showed that compounds 4r and 5m had the potential to interact with the Eg5 binding site
via H-bond interactions to GLU116 and GLY117 residues. The results of our study strongly suggest that DHPM and
pyridine derivatives inhibit important tumorigenic features of breast and gastric cancer cells. Our results may be helpful
in the further design of DHPMs and pyridine derivatives as potential anticancer agents.
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1. Introduction
A common approach in cancer chemotherapy is the development of drugs that interrupt the mitosis phase of
cell division. The mitotic spindle is an important target in cancer chemotherapy, and a fundamental spindle
motor protein is kinesin Eg5, which is considered as an important therapeutic target due to its specific role
during mitosis in assembly [1,2].
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In recent years, 3,4-dihydropyrimidine-2(1H)-ones (DHPMs) have been identified as compounds that
specifically inhibit Eg5 function. Since mitotic kinesins are exclusively involved in the formation of the mitotic
spindle, the inhibition of Eg5 by DHPMs is considered an attractive approach to cancer treatment [3]. It was
reported that monastrol has an antitumor effect on various cancer cell types, such as breast, renal, and glioma
cell lines. Unlike taxol, this compound, as an antimitotic agent, has not showed neuronal cytotoxicity [4,5].
Recently, DHPMs have played a significant role in medicinal chemistry due to their wide range of biological
activities, such as antitumor [6], antiinflammatory [7], antihypertensive [8], and antiviral [9] activities, and,
most importantly, as calcium channel modulators [10]. Moreover, pyridine derivatives are known to have
multiple biological effects, such as anticancer [11], anti-HIV virus [12], antimicrobial [13], antiin?ammatory [14]
cardiotonic [15], and antiparkinsonism properties [16]. Several 4,6-diaryl-substituted and tricyclic 2-amino-3-
cyanopyridines have shown antitumor effects on human breast cancer cell lines T-47D and ZR-75-1 [17,18].
Most cancer drugs usually show high toxicity and/or multidrug resistance of tumors. Hence, the develop-
ment of novel bioactive compounds with anticancer effects is a very important issue [17,18]. Much research has
been conducted on pyrimidine and pyridine derivatives; however, the simple synthesis and cytotoxic activity
profiles of 2,6-diaryl-substituted pyridine and DHPMs on the human breast adenocarcinoma cell line (MCF-7),
gastric adenocarcinoma (AGS), and human embryonic kidney (HEK293) cells has not been explored thus far.
This paper reports the simple and efficient synthesis, cytotoxic assessment, and molecular docking studies of
2,6-diaryl-substituted pyridine and DHPM derivative scaffolds.
In light of the importance of DHPM derivatives, several improved methods have been reported for the
preparation of these compounds using various catalysts [19–22]. Although multiple methods have been reported
for preparing functionalized pyridine derivatives [23–26], most require multiple steps, a large excess of expensive
reagents, long reaction times, toxic solvents, and forceful reaction conditions.
In view of these reports, and in continuation of our previous work towards the development of efficient
and environmentally benign heterogeneous catalysts [27–30], we synthesized some DHPM/pyridine derivatives
in the presence SO3H-substituted silica-coated cobalt-based (CoFe2O4@SiO2 -SO3H) magnetic nanoparticles
(MNPs) as a highly efficient catalyst under solvent-free conditions with microwave irradiation (Schemes 1 and 2)
to evaluate their cytotoxic effects on MCF-7, AGS, and HEK293 cells. The CoFe2O4@SiO2 -SO3H MNPs were
synthesized as highly efficient magnetic nanocatalysts and employed for the synthesis of DHPM and pyridine
derivatives under solvent-free conditions with microwave irradiation (Schemes 1 and 2). Finally, the screened
derivatives were subjected to molecular docking simulations to explore their binding potential toward the Eg5
enzyme as a validated cancer target for these compounds.
 
Scheme 1. Synthesis of DHPMs in the presence of the CoFe2O4@SiO2 -SO3H MNPs.
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Scheme 2. Synthesis of 2-amino-4,6-diarylnicotinonitriles in the presence of CoFe2O4@SiO2 -SO3H MNPs.
2. Results and discussion
2.1. Catalyst characterization
An easy and efficient procedure was employed for the preparation of the CoFe2O4@SiO2 -SO3H core-shell
composite with CoFe2O4 spheres as the core and SiO2 -SO3H MNPs as the shell. There were a great number
of hydroxyl groups on the surface of the CoFe2O4@SiO2 -SO3H MNPs. The MNPs were simply coated with
amorphous SiO2 using the conventional sol-gel procedure and then functionalized by SO3H groups via simple
mixing with ClSO3H.
The structural characteristics of the CoFe2O4@SiO2 -SO3H MNPs were studied via TGA, SEM, FTIR,
and XRD techniques. The FTIR spectra of the CoFe2O4 , CoFe2O4@SiO2 , and CoFe2O4@SiO2 -SO3H are
represented in Figure 1. Two characteristic bands at 3300 and 592 cm−1 were related to the O-H stretching of
the sulfonic acid functional group and M-O vibration, respectively [31]. The bands that appeared at 1218 and
1124 cm−1 belonged to the sulfonyl group that overlapped with a stronger peak of Si-O at 1091 cm−1 . The
peaks at 1061, 1073, and 474 cm−1 confirmed the presence of Si–O–Si moiety in the nanocatalyst structure
[32,33]. The presence of peaks at ranges of 592–629 cm−1 and 1091–1218 cm−1 can be considered as similarities
of the 3 stages (a, b, and c) and 2 stages (b and c), respectively. The peaks that appeared at 1218 and 1124
cm−1 , which overlapped with the stronger peak of Si-O at 1091 cm−1 , were the differences of stages a and c.
The TGA curve of CoFe2O4@SiO2 -SO3H MNPs demonstrated the weight losses of the surface hydroxyl
groups and physically adsorbed solvent below 150 °C (Figure 2). Moreover, weight loss in the range of 600–800
°C was attributed to the weight loss of the SO3H groups in the nanocatalyst structure [34].
The crystallinity and the average diameter of the CoFe2O4@SiO2 -SO3H MNPs were obtained from the
analysis of the XRD pattern. The XRD pattern of the CoFe2O4@SiO2 -SO3H MNPs is presented in Figure
3, where it can be seen that the CoFe2O4@SiO2 -SO3H MNPs exhibited 5 characteristic bands at the 2θ
values of (220), (311), (400), (511), and (440), corresponding to a cubic spinal structure of CoFe2O4 (card no.
00-001-1121) [35]. The diameter of the CoFe2O4@SiO2 -SO3H MNPs was measured by XRD employing the
Debye-Scherrer equation at about 33 nm.
The SEM analysis revealed that the CoFe2O4@SiO2 -SO3H MNPs had a nanocrystalline structure with
nanodimensions ranging from 22.98 to 45.30 nm (Figure 4).
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Figure 1. FTIR spectra of (a) CoFe2O4 , (b)
CoFe2O4@SiO2 , and (c) CoFe2O4@SiO2 -SO3H MNPs.
Figure 2. TGA curves of CoFe2O4@SiO2 -SO3H MNPs.
Figure 3. XRD pattern of CoFe2O4@SiO2 -SO3H MNPs.
2.2. Catalytic effect of CoFe2O4@SiO2 -SO3H for the synthesis of DHPM and 2-amino-4,6-
diarylnicotinonitrile derivatives
After characterization of the catalyst, its catalytic effect on the synthesis of DHPMs was evaluated. To optimize
the reaction conditions, the reaction of 4-chlorobenzaldehyde, ethyl acetoacetate, and urea was evaluated under
different microwave powers in the presence of various amounts of CoFe2O4@SiO2 -SO3H as a model reaction
(Tables 1 and 2). In the absence of a nanocatalyst, only trace amounts of the products could be obtained (Table
1).
Table 1. Effect of the CoFe2O4@SiO2 -SO3H nanocatalyst amount on the synthesis of DHPMs.
Entry Catalyst (g) Time (min) Yield (%)
1 None 8 Trace
2 0.010 8 68
3 0.015 3 90
4 0.020 3 79
Reaction situations: 4-Chlorobenzaldehyde 1 (1 mmol),
urea 2 (2 mmol), and ethyl acetoacetate 3 (1.5 mmol)
under solvent-free conditions with microwave irradiation at 400 W.
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Figure 4. SEM image of CoFe2O4@SiO2 -SO3H MNPs.
Table 2. Effect of microwave power on the synthesis of DHPMs in the presence of CoFe2O4@SiO2 -SO3H.
Entry Microwave power (W) Time (min) Yield (%)
1 300 3 63
2 350 3 72
3 400 3 90
4 450 3 80
Reaction conditions: 4-Chlorobenzaldehyde 1 (1 mmol), urea 2 (2 mmol),
ethyl acetoacetate 3 (1.5 mmol), and CoFe2O4@SiO2-SO3H (0.015 g),
with microwave irradiation under solvent-free conditions.
After reaction optimization, the reactions of ethyl acetoacetate with different aldehydes (1a–1r) and urea
were performed in the presence of CoFe2O4@SiO2 -SO3H MNPs under microwave irradiation within 3–5 min
(Table 3).
Moreover, the 2-amino-4,6-diarylnicotinonitrile derivatives were synthesized using CoFe2O4@SiO2 -SO3H
MNPs under MW irradiation according to the method presented in a previous work [36] (Table 4).
In order to investigate catalyst reusability, after completion of the reaction, the catalyst was separated
by an external magnet and then washed with ethanol. The CoFe2O4@SiO2 -SO3H MNPs could be reused at
least 5 times (Table 5).
Generally, employing the CoFe2O4@SiO2 -SO3H MNPs gave an efficient method for the preparation of
pure products in excellent yields.
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Table 3. Synthesis of DHPM derivatives by 3-component condensation of aldehydes, urea, and ethyl acetoacetate in
the presence of CoFe2O4@SiO2 -SO3H.
No. Ar Product Time (min) Yield (%) Mp (°C) Ref.
1 Ph 4a 5 90 198–201 [37]
2 4-Me-Ph 4b 5 86 206–209 [38]
3 4-Cl-Ph 4c 3 90 212–215 [37]
4 3-Cl-Ph 4d 5 92 192–194 [39]
5 2-Cl-Ph 4e 5 89 210–213 [37]
6 4-Br-Ph 4f 3 86 211–214 [40]
7 3-Br-Ph 4g 5 89 186–189 [40]
8 4-NO2-Ph 4h 3 92 221–224 [37]
9 3-NO2-Ph 4i 3 90 225–227 [37]
10 3,4-(MeO)2-Ph 4j 5 86 173–175 [41]
11 4-OH-Ph 4k 5 87 254–257 [42]
12 4-OMe-Ph 4l 5 86 203–205 [37]
13 Thiophene 4m 5 88 215–217 [37]
14 4-(Me)2N-Ph 4n 5 88 250–253 [38]
15 4-F-Ph 4o 3 90 175–177 [43]
16 3-F-Ph 4p 5 92 209–211 [40]
17 2-F-Ph 4q 3 89 231–233 [39]
18 2,6-(Cl)2-Ph 4r 3 90 227–230 [38]
Reaction conditions: Benzaldehyde 1a–1r (1 mmol), ethyl acetoacetate 2 (1.5 mmol), urea 3 (2 mmol),
and CoFe2O4@SiO2-SO3H (0.015 g) with microwave irradiation at 400 W under solvent-free conditions.
2.3. Biological assessments
2.3.1. Cytotoxicity
Two human cancer model cell lines (MCF-7 and AGS) were treated with various concentrations (0.39–200
µg/mL) of pyrimidine and pyridine derivatives. Interestingly, the primary screenings exhibited high cytotoxic
effects against AGS and MCF-7 cells with fewer side effects (low cytotoxic effects) on normal cells (HEK293).
Cell viabilities were recorded after treatment for 24 and 48 h. As shown in Figure 5, after treatment for 24 and
48 h, compound 4r induced death in ≥50% of AGS cells, while compound 4j exhibited the effect after 48 h at
different concentrations.
In the case of pyridine derivatives, 5g and 5m were less cytotoxic against HEK293 cells when compared to
the other analogs. These compounds (5g and 5m) demonstrated the highest effects, which led to a considerable
decrease in cell viability in MCF-7 cells at different concentrations (Figure 6).
Among the compounds, compound 4r exhibited the strongest cytotoxic effect towards the MCF-7 cell
line, with an IC50 of 0.17 µg/mL. Moreover, compounds 4j and 4r showed superior cytotoxic activity against
the AGS cell line after 48 h, with an IC50 of 4.90 and 4.97 µg/mL, respectively. Moreover, compounds 5g, 5m,
and 4m were more potent against the MCF-7 cell line, with an IC50 of 71.94, 82, and 128 µg/mL, respectively.
In contrast, compounds 5e (IC50 of 288.56 µg/mL), 5c (IC50 of 307 µg/mL), and 5j (IC50 of 615.88 µg/mL)
were less toxic for the MCF-7 cell line (Tables 6 and 7). As shown in Table 7, it was found that, with the
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Table 4. Four-component condensation of aldehydes, acetophenone, malononitrile, and ammonium acetate in the
presence of CoFe2O4@SiO2 -SO3H for the preparation of 2-amino-4,6-diarylnicotinonitrile.
No. R Product Time (min) Yield (%) Mp (°C) Ref.
1 H 5a 2 89 187–189 [44]
2 4-Cl 5b 1.5 90 180–182 [44]
3 3-Cl 5c 2 87 168–170 [36]
4 2-Cl 5d 2 90 199–201 [45]
5 4-F 5e 1.5 92 164–166 [45]
6 3-F 5f 2 88 162–165 [36]
7 2-F 5g 2 85 178–180 [36]
8 4-NO2 5h 2 87 216–218 [45]
9 3-NO2 5i 2 88 208–210 [45]
10 4-Br 5j 1.5 92 186–188 [45]
11 4-CN 5k 1.5 92 185–187 [45]
12 2,6-(Cl)2 5l 2 86 174–176 [36]
13 2,4-(Cl)2 5m 1.5 89 179–181 [36]
Reaction conditions: Benzaldehyde 1a–1m (1 mmol), acetophenone 2 (1 mmol),
malononitrile 3 (1 mmol), and ammonium acetate 4 (1 mmol) with 0.012 g
CoFe2O4@SiO2-SO3H under solvent-free conditions with microwave irradiation at 600 W.
Table 5. Reusability of the CoFe2O4@SiO2 -SO3H nanocatalyst.
Run Yield (%)
Fresh 90
First 90
Second 88
Third 88
Fourth 86
Reaction conditions:
4-Chlorobenzaldehyde 1
(1 mmol), urea 2 (2 mmol),
ethyl acetoacetate 3 (1.5 mmol),
and CoFe2O4@SiO2-SO3H
(0.015 g) with microwave
irradiation at 600 W
under solvent-free conditions.
presence of an electronegative substituent at the ortho position, the cytotoxic activity had increased. In other
words, in pyridine derivatives, the cytotoxic activity against the MCF-7 cell increased with the transfer of a
substituent from para to ortho positions. Among the pyridine derivatives, the strongest and weakest cytotoxic
effects belonged to 5g (2-F derivative) and 5j (4-Br derivative), respectively. It was shown that the cytotoxic
effect decreased by a greater amount with the para substituent in the brominated compounds.
2.4. Molecular docking
Recent drug discovery methods have relied heavily on the crystallographic 3D structural data of biomolecular
compounds. Numerous crystallographic records in the Protein Data Bank (PDB) have facilitated the effective-
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Figure 5. Treatment of AGS cells (24 and 48 h) with DHPMs derivatives (4j and 4r) (200–1.56 µg/mL) and cell
viability screening via MTT assay. Data are represented as mean ±SD (n = 3). *P <0.05, **P <0.01, ***P <0.001, ns:
not significant.
Table 6. Cytotoxicity results for compounds 4j and 4r in the MTT assessment.
Entry Compound IC50 (µg/mL)
AGS (24 h)
IC50 (µg/mL)
AGS (48 h)
IC50 (µg/mL)
MCF-7
IC50 (µg/mL)
HEK293
1 4j 267.7 04.90 510 >200
2 4r 29.98 04.97 0.17 >200
Table 7. Cytotoxicity results of pyridine analogous in the MTT assessment.
Entry Compound IC50 (µg/mL)
MCF-7
IC50 (µg/mL) HEK293
1 4m 128.00 146.25
2 5c 307.00 >1000
3 5e 288.56 157.24
4 5g 71.94 949.59
5 5j 615.88 195.00
6 5m 82.90 258.67
ness of molecular modeling research aiming at Eg5 as a validated target for cancer. One of the most popular
molecular modeling strategies is docking, which provides a technique to simulate the stereoelectronic fitness of
receptors and ligands via the lowest energy pathway.
2.4.1. Docking validation
Accuracy of a typical docking protocol could be examined by self-docking measurement of the root mean square
deviation (RMSD) in the docked and crystallographic poses. The docking validation method was conducted for
11 PDB structures of Eg5. Enzyme conformations were selected based on consideration of the relative similarity
of the cocrystallized ligands to the structures of the DHPM and the crystallographic resolutions. Regarding the
RMSD values and conformation population in the top-ranked cluster of an AutoDock output file, the enzyme
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Figure 6. Treatment of MCF-7 and HEK293 cells (24 h) with compounds 4m, 5c, 5e, 5g, 5j, and 5m (0.39–200
µg/mL).
structure with PDB code 2IEH was selected as the most appropriate crystallographic structure for further
modeling studies. Docking validation results are illustrated in Table 8. Moreover, Figure 7 shows the docked
MOY and the cocrystallized one in almost the same positions among the receptors (RMSD = 0.61 ?) that
confirmed validation of the docking protocol.
2.4.2. Docking analysis
The estimated free binding energies, the populations in the optimum clusters, and the calculated inhibition
constants (k i) of the synthesized compounds extracted from the docking studies are summarized in Table 9,
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Table 8. Results of docking validation for various holo PDB structures of Eg5 with 50 GA runs and 2.5 ×106 maximum
number of energy evaluations.
PDB code Resolution (Å) Population in the optimum cluster (%) RMSD from references structure (Å)
3K3B 2.40 50 0.355
2X2R 2.20 23 0.610
2IEH 2.70 50 0.610
2X7D 2.30 50 0.850
2X7C 1.90 48 0.740
4A51 2.70 19 0.779
3KEN 2.50 48 0.814
4BBG 2.75 31 0.892
2X7E 2.40 50 0.897
2XAE 2.60 32 0.931
4A50 2.75 48 1.951
Figure 7. Binding poses of MOY (cognate ligand) within the Eg5 active site (PDB ID: 2IEH) in docked blue stick and
crystallographic red stick states (RMSD 0.61 ?).
where it can be seen that compounds 4r and 5m showed the highest free energies of binding, which indicated
their probable binding ability to Eg5 residues. These products had the highest values in their groups, because
there were 2 kinds of molecules. Structure binding explorations proved that H-bonds and hydrophobic contacts
were responsible for such interactions. Compound 4r interacted with Glu116 to ensure the stability of the
α -helix [46]. Compound 5m exhibited hydrogen bonds with Glu118 and Gly117 (Figures 8 and 9).
To get more data, a 2D schematic presentation of the ligand–receptor interactions for the 3 compounds,
with high energy and good cytotoxic activity, is displayed in Figures 10–12. According to the schematic binding
representations, H-bond interaction could also be detected between the Glu116 and NH (ring) of compound
10
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Table 9. Results of docked DHPs and pyridine derivatives within the Eg5 active site (PDB code: 2IEH).
Compound Population in the optimum clusters (%) Estimated Ki (µM) Estimated free energy of binding (Kcal/mol)
4j 14 13.00 –6.67
4m 28 30.97 –6.15
4r 13 02.39 –7.67
5c 42 0.352 –8.80
5e 24 0.941 –8.22
5g 50 0.764 –8.24
5j 50 0.312 –8.88
5m 50 0.105 –9.52
Figure 8. 3D interaction schemes of a docked ligand (4r)
in the Eg5 active site (PDB ID: 2IEH).
Figure 9. 3D interaction scheme of a docked ligand (5m)
in the Eg5 active site (PDB ID: 2IEH).
4r, whereas H-bond donor interaction between Glu118 and NH (ring) was recorded for compound 5m. The
docking analysis revealed that all of the compounds interacted with Eg5 in an appropriate manner, with the
dominance of a H-bond donor group in the DHPM ring.
In past reports, the existence of some drawbacks, such as harsh conditions, toxic organic solvents, long
reaction times, high costs, difficult reuse, low product yields, and eco-unfriendly catalysts have limited the use of
these methods [19–26]. Therefore, this paper reports a novel, simple, and efficient strategy for the preparation of
pyrimidine and pyridine derivatives with anticarcinogenic potential, without solvent, under microwave irradia-
tion, and using magnetic cobalt ferrite nanoparticles as the catalyst. Based on the literature, thio-derivatives of
monastrol (pyrimidine scaffold) have displayed relevant antiproliferative effects against melanoma (UACC.62),
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kidney (786-0), breast (MCF-7), ovarian (OVCAR03), and particularly colon (HT-29) cancer cell lines [5], while
the results herein strongly suggest that DHPMs inhibit important tumorigenic features of AGS cancer cells,
leading them to death. Among the pyridine derivatives, a series of 2-amino-3-cyano-6-(1H-indol-3-yl)-4-phenyl
pyridine derivatives have shown cytotoxic activity against four human cell lines (A549, H460, HT-29, and
SMMC-7721) that form preliminary structure–activity relationships, and the introduction of halogen groups
into the benzene ring was essential for their cytotoxic activity [11]. To the best of our knowledge, the cytotoxic
assessment of five derivatives, 5c, 5f, 5g, 5l, and 5m, has not been previously reported, and among them,
compounds 5g and 5m exhibited good cytotoxic activity against the MCF-7 cell line. Affinity maps of the
ligand–enzyme showed that derivatives with halogen groups in the benzene ring had the potentiality to interact
with the Eg5 binding site via H-bond interactions. Based on the reports and results herein, hydrogen bond
formation and hydrophobic interactions were the key factors affecting the inhibitory effect of these compounds
[1].
Figure 10. 2D interaction scheme of a DHPM derivative
(4r) in the Eg5 active site (PDB ID: 2IEH).
Figure 11. 2D interaction scheme of a pyridine derivative
(5g) in the Eg5 active site (PDB ID: 2IEH).
3. Experimental
3.1. Chemicals
All chemical materials, solvents, salts, and other chemical materials were commercially purchased from Sigma-
Aldrich (St. Louis, MO, USA), Fluka (Dorset, England, UK), and Merck (Darmstadt, Germany). Thin-layer
chromatography (TLC) was used to follow the reactions.
3.2. Synthesis
3.2.1. Synthesis of CoFe2O4@SiO2 -SO3H
This catalyst was prepared in three steps according to method presented in a previous report [36].
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Figure 12. 2D interaction scheme of a pyridine derivative (5m) in Eg5 active site (PDB ID: 2IEH).
3.2.2. Experimental procedure for the synthesis of DHPM and 2-amino-4,6-diarylnicotinonitrile
derivatives
After characterization of the catalyst, its catalytic effect on the formation of the DHPMs and 2-amino-4,6-
diarylnicotinonitrile derivatives was evaluated.
In the first step, in order to optimize the reaction conditions, the reaction of 4-chlorobenzaldehyde,
ethyl acetoacetate, and urea under different microwave powers in the absence and presence of various amounts
of CoFe2O4@silica sulfuric acid were performed as a model reaction (Tables 1 and 2). The progress of the
reaction was monitored via TLC after every minute (EtOAc and n -hexane, 6:10). After completion of the
reaction, the solid product was filtered and the pure product was obtained by recrystallization from hot ethanol.
The CoFe2O4@SiO2 -SO3H nanocatalyst was subsequently washed with ethanol and then dried for use in the
next catalytic cycles.
For optimization of the catalyst amount, different quantities of catalyst were evaluated. As can be seen
in Table 1, in the absence of a nanocatalyst, only trace amounts of the products could be achieved. When
the reaction was performed in the presence of 0.015 g of the nanocatalyst, an excellent yield of products was
achieved (Table 1, entry 3). Finally, 0.015 g of the nanocatalyst and 400 W of microwave irradiation under
solvent-free conditions were obtained as the optimum conditions.
After optimization of the reaction conditions, reactions of ethyl acetoacetate with a wide range of
substituted aldehydes (1a–1r) and urea were performed in the presence of CoFe2O4@silica sulfuric acid MNPs
under solvent-free conditions with microwave irradiation within 3–5 min (Table 3). The yields of all of the
reactions were good to excellent. It was found that aldehydes with electron-donating groups represented lower
reactivity when compared with aldehydes with electron-withdrawing groups.
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Next, the 2-amino-4,6-diarylnicotinonitrile derivatives were synthesized using CoFe2O4@SiO2 -SO3H as
a nanocatalyst under microwave radiation according to the method presented in a previous project [36]. In
a 5-mL microwave reaction vessel, a mixture of ammonium acetate 4 (1.5 mmol), malononitrile 3 (1 mmol),
acetophenone 2 (1 mmol), an aromatic aldehyde (1a–1m) (1 mmol), and CoFe2O4@silica sulfuric acid (0.012
g) was reacted for 1–2 min. The reaction progress was elucidated via TLC after every minute (n -hexane and
EtOAc, 10:6). It was found that aldehydes with electron-withdrawing groups in the ortho and meta positions
reacted slower than those in the para position. This catalyst was separated from the mixture using an external
magnet and washed for the recycling tests. All of the products were known compounds that were characterized
by melting point, IR, and 1H NMR and 13C NMR spectra.
3.3. Structural characterization
Proton NMR spectra were recorded on a Bruker DRX-250 Avance spectrometer (Billerica, MA, USA) at 250.13
MHz. Proton chemical shifts were reported in ppm (δ) relative to the internal standard tetramethylsilane
(TMS, δ0.0 ppm) or with the solvent reference relative to the TMS employed as an internal standard (CDCl3 ,
δ7.26 ppm). Carbon NMR spectra were recorded on a Bruker DRX-250 Avance spectrometer at 62.90 MHz
with complete proton decoupling. Carbon chemical shifts were reported in ppm (δ) relative to TMS with
the respective solvent resonance as the internal standard (CDCl3 , δ77.0 ppm). The probe temperature was
regulated at 27 °C. For each spectrum, 64 scans were collected using 30°pulses with a spectral width of 20.5 ppm,
acquisition time of 2.67 s, and recycle delay of 3 s. IR spectra were recorded on KBr discs on a Jasco 6300 FTIR
spectrometer (Tokyo, Japan). The microwave-assisted approaches were performed in a Milestone microwave
oven (Sorisole, Italy) operating at 1600 W. Melting points were recorded on an Electrothermal 9100 apparatus
(LABEQUIP Ltd., Markham, Canada). The structural characteristics of CoFe2O4@SiO2 -SO3H MNPs were
studied via XRD with an X’Pert-PRO advanced diffractometer (Malvern Instruments, Malvern, UK) using
Cu (Ka) radiation (wavelength: 1.5406 Å). The morphologies and sizes of the particles were studied using a
scanning electron microscope (KYKY Co., Beijing, China, model: EM 3200).
3.4. Spectral data of some products
3.4.1. 2-Amino-4-(3-chlorophenyl)-6-phenylnicotinonitrile (5c)
Yellow crystal, yield: 87%, mp 168–170 °C; IR (KBr): 3469 and 3305 (NH2) , 2205 (CN), 1635 (C=N), 1578
(C=C), 1258 (C-N); 1H NMR (250.13 MHz, DMSO): δ 7.06 (s, 2H, NH2) , 7.30 (s, 1H, aromatic), 7.46–7.61
(m, 6H, aromatic), 7.74 (s, 1H, aromatic), 8.12 (d, 2H, aromatic, J = 3.5 Hz); 13C NMR (62.90 MHz,
CDCl3) : δ 110.99 (pyridine C-5), 116.68 (CN), 126.38, 127.32, 128.22, 128.81, 129.84, 130.20, 130.35, 134.90,
137.66, 138.61 (pyridine C-4), 153.51 (pyridine C-6), 160.17 (pyridine C-2) [36].
3.4.2. 2-Amino-4-(3-fluoroophenyl)-6-phenylnicotinonitrile (5f)
Cream solid, yield: 88%, mp 162–165 °C; IR (KBr): 3473 and 3311 (NH2) , 2206 (CN), 1645 (C=N), 1575
(C=C), 1234 (C-N); 1H NMR (250.13 MHz, DMSO): δH 7.03 (s, 2H, NH2) , 7.25 (s, 1H, aromatic), 7.34–7.47
(m, 5H, aromatic), 7.72 (t, 2H, aromatic, J = 5.5 Hz), 8.10 (d, 2H, aromatic, J = 5 Hz); 13C NMR (62.90
MHz, CDCl3) : δC 111.08 (pyridine C-5), 115.89 (d, 2JCF = 22.01 Hz), 116.24 (CN), 116.99, 127.32, 128.80,
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130.08 (d, 3JCF = 08.80 Hz), 133.00, 137.82, 154.00 (pyridine C-4), 160.25 (d, 1JCF = 250.97 Hz), 161.69
(pyridine C-6), 165.68 (pyridine C-2) [36].
3.4.3. 2-Amino-4-(2,6-dichlorophenyl)-6-phenylnicotinonitrile (5l)
Yellow crystal, yield: 86%, mp 174–176 °C; IR (KBr): 3489 and 3373 (NH2) , 2214 (CN), 1666 (C=N),
1577(C=C), 1215 (C-N); 1H NMR (250.13 MHz, DMSO): δ 7.18 (s, 2H, NH2) , 7.26 (s, 1H, aromatic), 7.46–
7.57 (m, 4H, aromatic), 7.65–7.68 (m, 2H, aromatic), 8.09 (d, 2H, aromatic, J = 2.5 Hz); 13C NMR (62.90
MHz, CDCl3) : δ 111.80 (pyridine C-5), 115.56 (CN), 127.39, 128.39, 128.79, 130.35, 130.84, 134.05, 137.63,
150.77 (pyridine C-4), 159.61 (pyridine C-6), 160.22 (pyridine C-2) [36].
3.4.4. 2-Amino-4-(2,4-dichlorophenyl)-6-phenylnicotinonitrile (5m)
Dark yellow crystal, yield: 89%, mp 179–181 °C; IR (KBr): 3480 and 3377 (NH2) , 2212 (CN), 1682 (C=N),
1615 (C=C), 1266 (C-N); 1H NMR (250.13 MHz, DMSO): δ 7.13 (s, 2H, NH2) , 7.21 (s, 1H, aromatic), 7.45–
7.47 (m, 3H, aromatic), 7.55–7.58 (m, 3H, aromatic), 8.09 (d, 2H, aromatic, J = 5 Hz); 13C NMR (62.90
MHz, CDCl3) : δ 111.98 (pyridine C-5), 116.05 (CN), 127.38, 127.55, 128.84, 130.16, 131.14, 133.23, 134.36,
136.11, 137.59, 151.87 (pyridine C-6), 159.87 (pyridine C-2) [36].
3.5. Cytotoxicity studies
FBS, PBS, trypsin, penicillin, streptomycin, DMSO, 3-[4,5-dimethyl thiazol-2-yl]-2,5-diphenyltetrazoliumbromide
(MTT), Triton X-100, and RPMI-1640 medium supplemented with 10% heat inactivated FBS were pur-
chased from Sigma-Aldrich. The AGS, HEK293, and MCF7 cell lines were purchased from the National Cell
Bank of Iran, Pasteur Institute of Iran, Tehran, Iran.
3.5.1. Cell culture and cell proliferation assay via MTT
In this research, the effects of synthesized compounds on the viability of MCF-7, AGS, and HEK cells were eval-
uated at various concentrations (0.39–200 µg/mL) utilizing 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium
bromide (MTT) assay [47]. After thawing, the cells were cultured in RPMI 1640 medium containing 10% FBS,
penicillin (100 U/mL), and streptomycin (100 mg/mL) at 37 °C in a humidified 5% CO2 incubator. The cells
were seeded in a 96-well plate at a density of 5000 cells per well (the cells were stained with trypan blue and
counted with a hemocytometer). The cells were incubated overnight at 37 °C before cell viability testing. A
stock suspension of each of the synthesized compounds at 50 mg/mL in distilled water was prepared. After
that, fresh suspensions of different concentrations of the synthesized compounds (2-fold serial dilutions from
0.39 to 200 µg/mL) were made using serial dilutions of the stock suspensions of the synthesized compounds
in the RPMI 1640 medium immediately before use. Next, 200 µL of suspension (different concentrations of
synthesized compounds) was added to each well of the micropentaplicates. The cells were incubated for 24 and
48 h under the same conditions. Wells without any synthesized compounds served as a negative control. The
experiments were performed in pentaplicate for each concentration. To assess cell survival, 100 µL of MTT so-
lution (2 mg/mL in PBS) was added to each well and incubated for 3 h at 37 °C to produce insoluble formazan.
Next, 100 µL of DMSO was added to dissolve the formazan crystals, and the absorbance was measured using an
Infinite M200 ELISA plate reader (Tecan, Männedorf, Switzerland) at 570 nm, with 630 nm as a reference wave
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length. The percentage of cell viability was calculated via the formula (A test/Acontrol) ×100, in which A test is
the average absorbance of the treated cells and Acontrol is the average absorbance of the negative control [47].
3.6. Molecular docking
ChemDraw Ultra 8 (2D), ChemDraw 3D, AutoDock 4.2 (ADT1.5.4), Accelrys Viewer Lite 5.0, LigPlot, and
Notepad++ were used.
3.6.1. Study of molecular docking
Studies of flexible-ligand docking were performed using AutoDock version 4.2. The PDB was employed to
retrieve all holo crystallographic structures of Eg5 with PDB codes 3K3B [48], 2X2R [49], 2XAE [49], 2IEH
[50], 2X7D [51], 2X7C [51], 2X7E [51], 4A51 [52], AND4A50 [52], and 3KEN [53] in this work.
All crystallographic water molecules and cognate ligands (MOY) were eliminated from the original
receptor structure for the provision of a target protein as a model (PDB code: 2IEH). All of the procedures for
the target/ligand preparation were conducted according to previous reports [54]. LIGPLOT was used for the
schematic 2D representations of the ligand-receptor interactions [55].
3.7. Analysis of statistical data
Cytotoxicity assessment of the cell lines were performed in pentaplicate, and the results were computed as mean
±SD. The experimental results were analyzed using one-way ANOVA analysis in SPSS 16.0 for Windows (SPSS
Inc., Chicago, IL, USA) and P <0.05 was considered significant. The IC50 values were calculated by nonlinear
regression analysis using Finney probit analysis in SPSS.
3.8. Conclusions
In the present work, a very facile and efficient method was reported for the synthesis of pyrimidine and pyridine
derivatives in the presence of CoFe2@SiO2 -SO3H as a recoverable catalyst under microwave irradiation and
solvent-free conditions. The results revealed that the synthesized DHPM derivatives had the potentiality to bind
to the Eg5 binding site (4r and 5m) via H-bond interactions and hydrophobic contacts with GLU116, GLU118,
and GLY117 residues. Biological assessments showed that the candidate molecules exhibited appropriate
cytotoxic effects against MCF-7 and AGS cells with low cytotoxicity to normal embryonic kidney (HEK293)
cells. Such advantages afforded the great potential of these compounds to be modified and developed towards
more selective anticancer agents.
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